Tosena-siroop

Product Beschrijving

Clinical Monograph: Toseina Syrup (Codeine Phosphate 2 mg/mL)

1. Classification and Chemical Overview

Toseina is an opioid-derived antitussive liquid formulation. The active component, codeine phosphate hemihydrate, is a semi-synthetic opium alkaloid derivative. Under the Anatomical Therapeutic Chemical (ATC) system, codeine used as a cough suppressant is classified under R05DA04.

• Product Context: Typically supplied as an oral solution (commonly in 100 ml or 250 ml bottles), requiring a calibrated measuring device.

• Controlled Status: Regulated strictly as a Prescription Only Medicine (POM) and a controlled substance internationally due to its opioid content, central nervous system activity, and liability for misuse, physical dependence, and recreational abuse (frequently referenced in illicit contexts such as “lean” or “drank”).

2. Mechanism of Action and Pharmacodynamics

Codeine acts centrally to suppress the cough reflex and provide mild analgesia:

• Medullary Cough Center Depression: The primary antitussive effect stems from codeine’s direct depressant action on the medullary cough center within the brainstem, elevating the threshold for cough.

• Prodrug Conversion: Codeine functions partially as a prodrug; while codeine itself possesses low affinity for opioid receptors, hepatic cytochrome P450 enzymes (specifically CYP2D6) metabolize a fraction of the dose into active morphine.

• $\mu$-Opioid Receptor Activity: Interaction with central $\mu$-opioid receptors modifies nociceptive processing and depresses central reflex loops.

3. Approved Clinical Indications and Dosing Scope

• Indications: Short-term management of painful or dry, non-productive coughs unresponsive to non-opioid antitussives.

• Exclusions: Strictly contraindicated in children under 12 years of age, pediatric patients undergoing tonsillectomy/adenoidectomy for obstructive sleep apnea, breastfeeding women, and known CYP2D6 ultra-rapid metabolizers.

Dosing & Administration Parameters:

• Adult Scope: Standard dosing ranges typically fall between 15 mg to 30 mg of codeine (equivalent to 7.5 mL to 15 mL of Toseina solution) taken every 4 to 6 hours as needed, keeping within safe maximum daily boundaries.

• Duration: Treatment duration must be kept as short as possible (typically not exceeding a few days) to avoid tolerance or dependence development.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and well absorbed from the gastrointestinal tract following oral ingestion.

• Metabolism: Undergoes hepatic first-pass metabolism. It is demethylated via CYP2D6 to morphine (active metabolite) and via CYP3A4 to norcodeine, with conjugation into codeine-6-glucuronide. Opmerking: Genetic variability in CYP2D6 can lead to unpredictable plasma morphine levels (ranging from therapeutic failure in poor metabolizers to severe toxicity in ultra-rapid metabolizers).

• Elimination: Excreted primarily through the kidneys, mostly as inactive conjugates and unchanged parent drug, with an elimination half-life averaging 3 to 4 hours.

5. Physiological Effects and Adverse Event Spectrum

Toseina depresses central nervous system functions and slows gastrointestinal transit.

Adverse Drug Reaction Spectrum

• Common ($\ge 1/100$ to $<1/10$): Drowsiness, sedation, dizziness, lightheadedness, nausea, vomiting, constipation, dry mouth.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Confusion, mood changes, pruritus, skin rashes, urticaria, palpitations, urinary retention, visual disturbances.

• Rare / Severe (<1/1,000): Respiratory depression, apnea, bronchospasm, severe allergic reactions, circulatory depression, and profound dependence or withdrawal syndromes upon cessation.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Known hypersensitivity to codeine or other opioids.

• Acute respiratory depression, chronic obstructive pulmonary disease (COPD) with severe respiratory reserve depletion, or acute asthma attacks.

• Risk of paralytic ileus, acute diarrheal conditions associated with pseudomembranous colitis, or known gastrointestinal obstruction.

• Pediatric populations under 12 years.

Key Drug Interactions

• CNS Depressants & Alcohol: Co-ingestion with alcohol, benzodiazepines, sedatives, or other opioids triggers profound, additive central nervous system and respiratory depression, risking fatal overdose.

• CYP2D6 Inhibitors (e.g., Quinidine): Can block the conversion of codeine to its active analgesic form, reducing efficacy.

• Anticholinergic Agents: Increases the risk of severe constipation, urinary retention, or paralytic ileus when combined with codeine’s antimotility properties.

Clinical Precautions and Warnings

• Misuse and Dependency Liability: Due to widespread recreational abuse trends involving codeine cough syrups, patients must be monitored for aberrant drug-seeking behaviors, dose escalation, or signs of psychological and physical dependence.

• Respiratory Risk: Exercise extreme caution in elderly or debilitated patients, or those with underlying pulmonary compromises, as standard doses can precipitate critical respiratory hypoventilation.